İ. ÇİÇİN Et Al. , "An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction," EUROPEAN JOURNAL OF BREAST HEALTH , vol.18, no.1, pp.63-73, 2022
ÇİÇİN, İ. Et Al. 2022. An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction. EUROPEAN JOURNAL OF BREAST HEALTH , vol.18, no.1 , 63-73.
ÇİÇİN, İ., Oukkal, M., Mahfouf, H., Mezlini, A., Larbaoui, B., Ben Ahmed, S., ... Errihani, H.(2022). An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction. EUROPEAN JOURNAL OF BREAST HEALTH , vol.18, no.1, 63-73.
ÇİÇİN, İRFAN Et Al. "An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction," EUROPEAN JOURNAL OF BREAST HEALTH , vol.18, no.1, 63-73, 2022
ÇİÇİN, İRFAN Et Al. "An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction." EUROPEAN JOURNAL OF BREAST HEALTH , vol.18, no.1, pp.63-73, 2022
ÇİÇİN, İ. Et Al. (2022) . "An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction." EUROPEAN JOURNAL OF BREAST HEALTH , vol.18, no.1, pp.63-73.
@article{article, author={İRFAN ÇİÇİN Et Al. }, title={An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction}, journal={EUROPEAN JOURNAL OF BREAST HEALTH}, year=2022, pages={63-73} }